Fibrogen Stock Analysis

FibroGen Stock Analysis Notes

About 71.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.92. FibroGen had not issued any dividends in recent years. The entity had 1:1 split on the September 8, 2009. FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people. To learn more about FibroGen call Thomas Neff at 415 978 1200 or check out https://www.fibrogen.com.

FibroGen Investment Alerts

FibroGen Upcoming and Recent Events

FibroGen Largest EPS Surprises

View All Earnings Estimates

FibroGen Thematic Classifications

FibroGen Stock Institutional Investors

Note, although FibroGen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

FibroGen Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 105.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate FibroGen's market, we take the total number of its shares issued and multiply it by FibroGen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

FibroGen Profitablity

The company has Profit Margin (PM) of (1.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.81) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.81.

Management Efficiency

FibroGen has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 24th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.

Technical Drivers

As of the 24th of April, FibroGen shows the Mean Deviation of 8.25, semi deviation of 9.3, and Downside Deviation of 10.77. FibroGen technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for FibroGen, which can be compared to its peers. Please confirm FibroGen coefficient of variation and the relationship between the jensen alpha and skewness to decide if FibroGen is priced favorably, providing market reflects its regular price of 0.9843 per share. Given that FibroGen is a hitting penny stock territory we advise to closely look at its total risk alpha.

FibroGen Price Movement Analysis

FibroGen Insider Trading Activities

FibroGen Predictive Daily Indicators

FibroGen Forecast Models

FibroGen's time-series forecasting models are one of many FibroGen's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary FibroGen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how FibroGen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling FibroGen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as FibroGen. By using and applying FibroGen Stock analysis, traders can create a robust methodology for identifying FibroGen entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. FibroGen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. FibroGen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

FibroGen stock analysis indicators help investors evaluate how FibroGen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading FibroGen shares will generate the highest return on investment. By understating and applying FibroGen stock analysis, traders can identify FibroGen position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.

Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.